News
Why Pfizer Stock Is Bouncing Back
For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But
Where Will AMD Stock Be in 5 Years?
With its shares more than doubling in 2023, Advanced Micro Devices (NASDAQ: AMD) has been a rewarding near-term investment. While the company's operational results are yet to match its impressive
EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
Why Pfizer Stock Was a Winner on Monday
The success of drug developers hinges on regulatory approvals for their medications. Considering that, it was hardly surprising that Pfizer (NYSE: PFE) stock had a good Monday on the market
Pfizer Slashed Its Guidance, but Is It Still a Smart Long-Term Buy?
Per updated guidance for its upcoming 2024 fiscal year, issued on Dec. 13, Pfizer (NYSE: PFE) has a bumpy road ahead -- at least for now. Amidst rapidly weakening coronavirus product revenue and
Forget Altria: 1 Ultra-High-Yield Dividend Stock I'd Rather Buy
Altria (NYSE: MO) and AT&T (NYSE: T) are two big names for many dividend investors, and it's no mystery why. While both stocks are trailing the S&P 500 over the past five years, they offer two of
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and
Better Income Stock: AT&T or AbbVie?
Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for
Is Amgen Stock a Buy Now?
This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen
Should You Worry About the Latest Wave of Bad News from Pfizer?
Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on
AT&T vs. T-Mobile: Which Is a Better Dividend Stock?
Telecom veteran AT&T (NYSE: T) has delivered dividends to investors for decades. Rival T-Mobile (NASDAQ: TMUS) followed suit in 2023, offering a dividend for the first time in company history with
Is AT&T an Excellent Dividend Stock to Buy for 2024?
Fool.com contributor Parkev Tatevosian reviews AT&T (NYSE: T) from the viewpoint of a passive income investor to determine whether it's an excellent dividend stock to buy.
*Stock prices used were
Great News for Rivian Stock Investors!
Fool.com contributor Parkev Tatevosian discusses a new arrangement between Rivian (NASDAQ: RIVN) and AT&T (NYSE: T) that has potential benefits for Rivian shareholders.
*Stock prices used were the
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light
Could Pfizer Stock Help You Become a Millionaire?
Having at least $1 million in the bank by retirement has long been a popular goal, but it isn't easy to accomplish. One of the best ways to do so is to invest in stocks, and the earlier one starts
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in
Why Rocket Lab Stock Just Dropped 10%
Good news became bad news for Rocket Lab USA (NASDAQ: RKLB) on Friday after the company announced its successful return to launch operations for the first time since a mishap resulted in the
EQS-News: Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
Where Will CRISPR Therapeutics Be in 5 Years?
CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug
Forget Nvidia: 2 Artificial Intelligence (AI) Stocks That Could Also Make You Rich
If there has been an overarching investment theme in 2023, it has probably been artificial intelligence (AI). Ever since the conversational chatbot ChatGPT launched in late 2022, tech giants have
3 Industry Stalwarts You Can Buy and Forget About
Don't have a lot of time to follow stocks and want some safe options for your portfolio? Three stocks that are big names within their respective industries and that can make for excellent long-term
3 No-Brainer Healthcare Stocks to Buy Right Now
Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite